Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study
Larry W. Kwak(The University of Texas MD Anderson Cancer Center), Christian Buske(University Hospital Ulm), Michinori Ogura(Japanese Red Cross Nagoya Daini Hospital), Olga Samoilova(Nizhny Novgorod Regional Clinical Hospital named after Semashko), Hideyuki Nakazawa(Shinshu University), Eduardo Yañez Ruiz(Universidad de La Frontera), Keum Young Ahn(Celltrion (South Korea)), Seok‐Goo Cho(The Catholic University of Korea Seoul St. Mary's Hospital), Edvard Zhavrid, Tobias Menne(Newcastle upon Tyne Hospitals NHS Foundation Trust), Juan‐Manuel Sancho(Hospital Universitari Germans Trias i Pujol), Marek Trněný(Charles University), Gayane Tumyan(Russian Cancer Research Center NN Blokhin), Sung Hyun Kim(Celltrion (South Korea)), Sang Joon Lee(Kosin University), Jin Seok Kim(University of Ulsan), Wojciech Jurczak(Jagiellonian University), Won-Seog Kim(Samsung Medical Center), Junji Suzumiya(Koga Hospital), N. V. Ilyin(Ministry of Health of the Russian Federation), Leslie Popplewell(City Of Hope National Medical Center), Aurelio López Martínez(Hospital Arnau de Vilanova), José Mariz(Instituto Português de Oncologia Francisco Gentil)
Cited by 14
Related Papers
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
|Journal of Clinical Oncology|2021|630
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2015|604
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2010|587
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|568